Clinical trials: Late Relapse of Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML)
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
The purpose of the study is to assess the efficacy and safety of elacytarabine versus investigator's choice treatment in patients with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- CLAVELA (NCT01147939)
- Testing
- Elacytarabine, Investigator's Choice
- Where
- 73 sites in United States, Australia and 11 more
- Volunteers
- 381 people
- Sponsor
- Clavis Pharma